{"id":261026,"date":"2026-09-22T11:20:52","date_gmt":"2026-09-22T05:50:52","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=261026"},"modified":"2026-09-22T11:20:54","modified_gmt":"2026-09-22T05:50:54","slug":"astrazeneca-pharma-india-stock-signals-investors-are-watching","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-stock-signals-investors-are-watching\/","title":{"rendered":"AstraZeneca Pharma India: 7 Stock Signals Investors Are Watching Right Now"},"content":{"rendered":"
<\/div>\n

AstraZeneca Pharma India CMP Rs 9,091.50. 52W range Rs 6,619.50 to Rs 10,691.00. Mcap Rs 22,686 crore. PE 113.92 vs sector 39.81.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

AstraZeneca Pharma India stock signals right now span an earnings picture, an FII holding of 2.70 percent, and a technical setup where the stock trades within its 52 week range of Rs 6,619.50 to Rs 10,691.00. Debt to equity stands at 0.04, and valuation sits at a P\/E of 113.92 against a sector average of 39.81. Corporate developments in the a science led pharmaceutical company focused on oncology, cardiovascular, renal, diabetes and respiratory therapy areas space add further context investors are tracking alongside these numbers. None of the seven signals here amounts to a buy or sell call on its own.<\/p>\n<\/div>\n

AstraZeneca Pharma India stock signals are unusually layered right now, with the company trading at Rs 9,091.50, the stock trades 15.0 percent below its 52 week high of Rs 10,691.00 and 37.4 percent above its 52 week low of Rs 6,619.50. AstraZeneca Pharma India is a well tracked name in the a science led pharmaceutical company focused on oncology, cardiovascular, renal, diabetes and respiratory therapy areas space, and no single headline captures where the stock stands today.<\/p>\n

This article does not make a buy, hold or sell call on AstraZeneca Pharma India. It lays out seven signals investors commonly watch, each sourced from the company’s latest exchange disclosures and financial statements, so readers can form their own view of what is currently working for the stock and what still needs to be watched.<\/p>\n

Click Here to Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n